Pharmather announces a method of use and composition of matter patent from the USPTO for its proprietary ketamine formulation, KETABET(TM).
Pharmather announces a method of use and composition of matter patent from the USPTO for its proprietary ketamine formulation, KETABET(TM).
Optimi Health's subsidiary has been named an approved supplier of psilocybin for Health Canada's SAP access program.
Mindset announces new insights in research on psychedelics molecules via its COPE initiative.
Novamind announces a "clinical pilot" aimed at bringing ketamine-assisted therapy to treat the mental health disorders of frontline healthcare workers.
Cybin announces its Q3 results, supported by a conference call. Cash as of Decemeber 31, 2021 of CAD$63.6 million.
Cybin announces receiving a composition of matter patent for its DMT-derived compound, CYB004 from the the USPTO.
A new U.S.-based psychedelics ETF will begin trading on the NYSE, symbol "PSYK".
Optimi Health announces receiving its Dealer's License from Health Canada, allowing the possession, production and sale of psilocybin.
Novamind will host a Phase II clinical trial by the Ketamine Research Foundation for ketamine therapy for the terminally ill.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now